Literature DB >> 11443709

Alternative 1-(13)C glucose infusion protocols for clinical (13)C MRS examinations of the brain.

A Moreno1, S Blüml, J H Hwang, B D Ross.   

Abstract

Clinical utility of (13)C MRS is limited by cost and long examination times. Three 1-(13)C glucose infusion protocols-a high-dose i.v., low-dose i.v., and oral administration of 1-(13)C glucose-were compared on a GE 1.5T MR scanner. Resolution and sensitivity were sufficient to identify (13)C glucose (1alpha and 1beta), glutamate (C1-C4), glutamine (C1-C4), aspartate (C2 and C3), lactate, alanine, and bicarbonate in brain spectra. The three protocols were efficacious, as measured by cerebral enrichment of 1-(13)C glucose (62%, 42%, and 38%) and its principal metabolite, 4-(13)C glutamate (13%, 11%, and 16%), respectively. Intravenous infusion of 1-(13)C glucose 0.23 g/kg body weight (low dose) provides equivalent information at one third the cost of previous regimes. Magn Reson Med 46:39-48, 2001. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443709     DOI: 10.1002/mrm.1158

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  10 in total

1.  Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study.

Authors:  Alexander P Lin; Frederick Shic; Cathleen Enriquez; Brian D Ross
Journal:  MAGMA       Date:  2003-02       Impact factor: 2.310

Review 2.  Glutamate and glutamine: a review of in vivo MRS in the human brain.

Authors:  Saadallah Ramadan; Alexander Lin; Peter Stanwell
Journal:  NMR Biomed       Date:  2013-10-04       Impact factor: 4.044

Review 3.  13C MRS studies of neuroenergetics and neurotransmitter cycling in humans.

Authors:  Douglas L Rothman; Henk M De Feyter; Robin A de Graaf; Graeme F Mason; Kevin L Behar
Journal:  NMR Biomed       Date:  2011-08-31       Impact factor: 4.044

4.  What have novel imaging techniques revealed about metabolism in the aging brain?

Authors:  Ai-Ling Lin; Douglas L Rothman
Journal:  Future Neurol       Date:  2014-05-01

5.  Glial dysfunction in abstinent methamphetamine abusers.

Authors:  Napapon Sailasuta; Osama Abulseoud; Kent C Harris; Brian D Ross
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-30       Impact factor: 6.200

6.  In vivo 13C magnetic resonance spectroscopy of human brain on a clinical 3 T scanner using [2-13C]glucose infusion and low-power stochastic decoupling.

Authors:  Shizhe Li; Yan Zhang; Shumin Wang; Jehoon Yang; Maria Ferraris Araneta; Amanda Farris; Christopher Johnson; Stephen Fox; Robert Innis; Jun Shen
Journal:  Magn Reson Med       Date:  2009-09       Impact factor: 4.668

Review 7.  Integration of enzyme kinetic models and isotopomer distribution analysis for studies of in situ cell operation.

Authors:  Vitaly A Selivanov; Tatiana Sukhomlin; Josep J Centelles; Paul W N Lee; Marta Cascante
Journal:  BMC Neurosci       Date:  2006-10-30       Impact factor: 3.288

Review 8.  Glucose metabolism following human traumatic brain injury: methods of assessment and pathophysiological findings.

Authors:  Ibrahim Jalloh; Keri L H Carpenter; Adel Helmy; T Adrian Carpenter; David K Menon; Peter J Hutchinson
Journal:  Metab Brain Dis       Date:  2014-11-21       Impact factor: 3.584

9.  Measurement of glucose metabolism in the occipital lobe and frontal cortex after oral administration of [1-13C]glucose at 9.4 T.

Authors:  Theresia Ziegs; Johanna Dorst; Loreen Ruhm; Nikolai Avdievitch; Anke Henning
Journal:  J Cereb Blood Flow Metab       Date:  2022-05-27       Impact factor: 6.960

Review 10.  (13)C-labelled microdialysis studies of cerebral metabolism in TBI patients.

Authors:  Keri L H Carpenter; Ibrahim Jalloh; Clare N Gallagher; Peter Grice; Duncan J Howe; Andrew Mason; Ivan Timofeev; Adel Helmy; Michael P Murphy; David K Menon; Peter J Kirkpatrick; T Adrian Carpenter; Garnette R Sutherland; John D Pickard; Peter J Hutchinson
Journal:  Eur J Pharm Sci       Date:  2013-12-20       Impact factor: 4.384

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.